This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

VX-950 and Peginterferon for Hepatitis C

This study has been completed.
Information provided by:
Vertex Pharmaceuticals Incorporated Identifier:
First received: November 7, 2005
Last updated: December 17, 2007
Last verified: December 2007
VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.

Condition Intervention Phase
Hepatitis C Drug: VX-950 Drug: peginterferon Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: A Phase 1b Viral Kinetic Study of VX-950 and Peginterferon in Hepatitis C

Resource links provided by NLM:

Further study details as provided by Vertex Pharmaceuticals Incorporated:

Primary Outcome Measures:
  • Viral kinetics

Secondary Outcome Measures:
  • Assess the safety of VX-950 in combination with peginterferon

Estimated Enrollment: 20
Study Start Date: October 2005
Study Completion Date: March 2006

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • infected with Hepatitis C virus

Exclusion Criteria:

  • contraindications to peginterferon therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00251199

Call for information
Homburg/Saar, Germany
Call for information
Amsterdam, Netherlands
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Study Director: Medical Monitor Vertex Pharmaceuticals Incorporated
  More Information Identifier: NCT00251199     History of Changes
Other Study ID Numbers: VX05-950-103
Study First Received: November 7, 2005
Last Updated: December 17, 2007

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections processed this record on September 21, 2017